NovaGo Therapeutics

NovaGo Therapeutics, founded in Switzerland in 2015, is a development-stage biotechnology company focused on human antibody therapies targeting vascular growth, nerve growth, and regeneration. NovaGo's proprietary human antibodies have the potential to become safe and effective treatments for ophthalmic and central nervous system indications. NovaGo’s proprietary antibodies can block the function of Nogo-A, one of the most potent and well-researched inhibitors of vascular and nerve growth.